Krajina: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
MIGLUSTAT
J-C HEALTH CARE LTD
A16AX06
CAPSULES
MIGLUSTAT 100 MG
PER OS
Required
ACTELION PHARMACEUTICALS LTD., SWITZERLAND
MIGLUSTAT
MIGLUSTAT
Zavesca is indicated for the oral treatment of mild to moderate type I Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
2023-05-31
ىلإ ً لااح هجوت ،ءاودلا نم أطخلاب لفط علب اذإ وأ ً اطرفم ً ارادقم أطخلاب تلوانت اذإ .ءاودلا ةبلع كعم رضحأو ،ىفشتسملا يف ئراوطلا ةفرغ ىلإ وأ بيبطلا دهوش ،غلم 3000 ىتح ةيئاود ريداقمبو ةيريرسلا ثاحبلأا يف اكسيڤاز لامعتسإ للاخ ةرقفلا يف ةروكذملا كلت هبشت ةيفاضإ ةيبناج ضارعأو ءاضيبلا مدلا تايرك يف ضافخنإ .ةرشنلا هذه نم 4 تقولا يف يلاتلا يئاودلا رادقملا لوانت ،بولطملا تقولا يف ءاودلا اذه لوانت تيسن اذإ .يسنملا رادقملا نع ضيوعتلل ً افعاضم ً ارادقم لوانت زوجي لا .بيبطلا رشتساو يدايتعلإا .بيبطلا ةيصوت بسح جلاعلا ىلع ةبظاوملا بجي ءاودلا لوانت نع تفقوت اذإ .بيبطلا ةراشتسإ نود نم جلاعلا نع فقوتلا زوجي لا رادقملا نم دكأتلاو ءاودلا عباط صيخشت بجي !ةمتعلا يف ةيودأ لوانت زوجي لا .كلذ رملأا مزل اذإ ةيبطلا تاراظنلا عض .ءاود اهيف لوانتت ةرم لك يف يئاودلا .يلديصلا وأ بيبطلا رشتسإ ،ءاودلا اذه لامعتسإ لوح ةيفاضإ ةلئسأ كيدل ترفوت اذإ ةيبناجلا ضارعلأا )4 .نيلمعتسملا ضعب ىدل ةيبناج ً اضارعأ ببسي دق اكسيڤاز لامعتسإ نإ ،ءاود لكب امك .اهنم ً ايأ يناعت لاأ زئاجلا نم .ةيبناجلا ضارعلأا ةمئاق نم شهدنت لا :ةيلاتلا ةيبناجلا ضارعلأا ىدحإ ترهظ اذإ يروف لكشب بيبطلا ىلإ ه ّ جوت :ةروطخ رثكلأا ةيبناجلا ضارعلأا ● تدهوش( نيمدقلا يتحارو نيديلا يف ليمنتلاب وأ زخ Prečítajte si celý dokument
1 Zavesca PI_Oct-2021 ZAVESCA® PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Zavesca® Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 100 mg miglustat. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Capsule, hard White capsules with “OGT 918” printed in black on the cap and “100” printed in black on the body. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zavesca is indicated for the oral treatment of mild to moderate type 1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable (see sections 4.4 and 5.1). Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease (see sections 4.4, and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Therapy should be directed by physicians who are knowledgeable in the management of Gaucher disease or Niemann-Pick type C disease, as appropriate. Posology _Dosage in type 1 Gaucher disease _ Adults The recommended starting dose for the treatment of patients with type 1 Gaucher disease is 100 mg three times a day. Temporary dose reduction to 100 mg once or twice a day may be necessary in some patients because of diarrhoea. Paediatric population The efficacy of Zavesca in children and adolescents aged 0-17 years with type 1 Gaucher disease has not been established. No data are available. _Dosage in Niemann-Pick type C disease _ Adult The recommended dose for the treatment of adult patients with Niemann-Pick type C disease is 200 mg three times a day. Paediatric population The recommended dose for the treatment of adolescent patients (12 years of age and above) with Niemann-Pick type C disease is 200 mg three times a day. 2 Zavesca PI_Oct-2021 Dosing in patients under the age of 12 years should be adjusted on the basis of body surface area as illustrated below: Body surface area (m 2 ) Recommended dose > 1.25 200mg three times a day > 0.88 - 1.25 Prečítajte si celý dokument